Comparison of distribution characteristics of metastatic bone lesions between breast and prostate carcinomas
- Authors:
- Chang-Yin Wang
- Guang-Yao Wu
- Mei-Juan Shen
- Kun-Wei Cui
- Ying Shen
View Affiliations
Affiliations: Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, P.R. China, Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, P.R. China
- Published online on: October 30, 2012 https://doi.org/10.3892/ol.2012.1005
-
Pages:
391-397
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The purpose of the present study was to investigate the distribution characteristics of bone metastases in breast and prostate carcinomas. Bone scintigraphies were performed in 504 cancer patients. We studied the correlation between the distribution and total number of metastatic bone lesions, and compared the distribution of metastatic bone lesions between breast and prostate carcinomas. In the early stage, the distribution in the thoracic vertebrae, lumbar vertebrae and pelvis of the metastatic lesions of the prostate carcinoma (81.0%, 47/58) was significantly higher than that of the breast carcinoma (41.7%, 63/151; χ2=27.6, P=0.000). The distribution of the lesions in the thoracic skeleton in the cases of the breast carcinoma (65.6%, 99/151) was significantly higher than that of the prostate carcinoma (27.6%, 16/58; χ2=24.8, P=0.000); however, the distributions in the advanced cases were not markedly different. The differences in the proportions of the metastatic lesions in the lumbar vertebrae (χ2=56.1, P=0.000) and ribs (χ2=39.1, P=0.000) in the cases of the prostate carcinoma, and in the sternum (χ2=31.2, P=0.000), skull (χ2=26.5, P=0.000) and femur (χ2=13.6, P=0.001) in the cases of the breast carcinoma were significant. Between the breast and prostate carcinomas, the differences in the proportions of the metastatic lesions of certain bones were also significant. In cases with few bone metastases, the proportion of sternum metastases of patients with breast carcinoma (17.9%) was significantly higher than that of patients with prostate carcinoma (1.7%; χ2=12.7, P=0.000); the proportion of metastases in the lumbar vertebrae of prostate carcinoma (39.7%) was significantly higher than that of breast carcinoma (13.9%; χ2=15.4, P=0.000); the proportion of rib metastases of breast carcinoma (27.2%) was significantly higher than that of prostate carcinoma (8.6%; χ2=9.6, P=0.002). In cases with extensive bone metastases, the proportions of metastatic lesions in the sternum and lumbar vertebrae in breast and prostate carcinomas were not significantly different (P>0.05). In conclusion, the distribution of bone metastases is correlated with the total number of metastatic bone lesions in breast and prostate carcinoma patients, and has different characteristics in different lesions.
View References
|
1
|
Lin K, Szabo Z, Chin BB and Civelek AC:
The value of a baseline bone scan in patients with newly diagnosed
prostate cancer. Clin Nucl Med. 24:579–582. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Conti G, La Torre G, Cicalese V, et al:
Prostate cancer metastases to bone: Observational study for the
evaluation of clinical presentation, course and treatment patterns.
Presentation of the METAURO protocol and of patient baseline
features. Arch Ital Urol Androl. 80:59–64. 2008.
|
|
3
|
Maffioli L, Florimonte L, Pagani L, Butti
I and Roca I: Current role of bone scan with phosphonates in the
follow-up of breast cancer. Eur J Nucl Med Mol Imaging. 31(Suppl
1): S143–S148. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Osmond JD III, Pendergrass HP and Potsaid
MS: Accuracy of 99mTc-diphosphonate bone scans and
roentgenograms in the detection of prostate, breast and lung
carcinoma metastases. Am J Roentgenol Radium Ther Nucl Med.
125:972–977. 1975.
|
|
5
|
Tofe AJ, Francis MD and Harvey WJ:
Correlation of neoplasms with incidence and localization of
skeletal metastases: An analysis of 1355 diphosphonate bone scans.
J Nucl Med. 16:986–989. 1975.PubMed/NCBI
|
|
6
|
Wilson MA and Calhoun FW: The distribution
of skeletal metastases in breast and pulmonary cancer: concise
communication. J Nucl Med. 22:594–597. 1981.PubMed/NCBI
|
|
7
|
Huang CY, Hsu HC, Chang CH, Tseng KF and
Fong YC: Prostate cancer with bone metastases: a clinical pofile.
Mid Taiwan J Med. 11:82–89. 2006.
|
|
8
|
Picchio M, Spinapolice EG, Fallanca F,
Crivellaro C, Giovacchini G, Gianolli L and Messa C: [11C] Choline
PET/CT detection of bone metastases in patients with PSA
progression after primary treatment for prostate cancer: comparison
with bone scintigraphy. Eur J Nucl Med Mol Imaging. 39:13–26.
2012.
|
|
9
|
Jacobson AF, Stomper PC, Jochelson MS,
Ascoli DM, Henderson IC and Kaplan WD: Association between number
and sites of new bone scan abnormalities and presence of skeletal
metastases in patients with breast cancer. J Nucl Med. 31:387–392.
1990.PubMed/NCBI
|
|
10
|
Mohammadzadeh M, Alikhah H and Zareh AG:
Comparison of bone scan with carbohydrate antigen 15-3 for
evaluation of bone metastasis of breast cancer. Pak J Biol Sci.
13:175–179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Even-Sapir E, Metser U, Mishani E,
Lievshitz G, Lerman H and Leibovitch I: The detection of bone
metastases in patients with high-risk prostate cancer:
99mTc-MDP Planar bone scintigraphy, single-and
multi-field-of-view SPECT, 18F-fluoride PET, and
18F-fluoride PET/CT. J Nucl Med. 47:287–297.
2006.PubMed/NCBI
|
|
12
|
Gate GF: SPECT bone scanning of the spine.
Semin Nucl Med. 28:78–94. 1998. View Article : Google Scholar
|
|
13
|
Even-Sapir E, Martin RH, Barnes DC,
Pringle CR, Iles SE and Mitchell MJ: Role of SPECT in
differentiating malignant from benign lesions in the lower thoracic
and lumbar vertebrae. Radiology. 187:193–198. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang CY and Zhang XY: Evaluation of
eikonic characteristic of skeletal metastasis of primary pulmonary
carcinoma with 99Tcm methylene diphosphonate
whole-body bone scans. Chinese-German J Clin Oncol. 9:435–440.
2010. View Article : Google Scholar
|
|
15
|
Cook GJ, Venkitaraman R, Sohaib AS, et al:
The diagnostic utility of the flare phenomenon on bone scintigraphy
in staging prostate cancer. Eur J Nucl Med Mol Imaging. 38:7–13.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mundy GR: Metastasis to bone: causes,
consequences and therapeutic opportunities. Nat Rev Cancer.
2:584–593. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bubendorf L, Schöpfer A, Wagner U, et al:
Metastatic patterns of prostate cancer: an autopsy study of 1,589
patients. Hum Pathol. 31:578–583. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ohtake E, Murata H and Maruno H: Bone
scintigraphy in patients with breast cancer: malignant involvement
of the sternum. Radiat Med. 12:25–28. 1994.PubMed/NCBI
|
